The global human papillomavirus (HPV) and cytomegalovirus (CMV) therapeutics market is characterized by high competitive rivalry. Mergers and acquisitions have emerged as a common go-to strategy for the leading players to expand their market position, finds Transparency Market Research (TMR) in a new study. Companies are investing large amounts in extensive research activities to improve product portfolio and distribution networks.
“The anticipated launch of new and improved drugs is likely to increase competitive rivalry in the near future,” says TMR’s lead analyst. The leading players in the global HPV therapeutics market are Valeant Pharmaceuticals International Inc., Fougera Pharmaceuticals, and Perrigo Company plc; while, the leading players in the global CMV therapeutics market are Roche AG, Clinigen Group plc, and Luitpold Pharmaceuticals Inc.
The global HPV therapeutics market was valued at US$1.64 bn in 2015 and is expected to rise to US$2.34 bn by 2020, expanding at a CAGR of 7.7% from 2014 to 2020. On the other hand, the valuation of the global CMV therapeutics was US$740.8 mn in 2015 and is estimated to expand at a CAGR of 1.5% during the same period, reaching a valuation of US$922 mn by 2020.
In terms of application, genital warts will remain dominant in the global HPV therapeutics market throughout the forecast period. The genital cancer segment will exhibit a CAGR of 8.8% during the forecast period. By application, retinitis will continue to dominate the global CMV therapeutics market until 2020, reaching US$241.3 mn by 2020.
Changing Lifestyles and Cultural Shift to Keep South America at Forefront
North America was the leading regional segment in the global HPV market in 2015. The major factor contributing to the growth of this region is the rising prevalence of HPV infections primarily due to the lack of awareness regarding HPV transmission, increasing sexually active population, and rising international migration. The South America market will exhibit a noteworthy CAGR of 10.4% during the same period due to a cultural shift and changing lifestyles. Geographically, North America will be the dominant segment in the global CMV therapeutics market, rising at a CAGR of 1.5% during the forecast period.
Severe Side Effects Associated with Vaccines to Bode Well for Sales of HPV Therapeutics
The rising prevalence of HPV infections in developing and underdeveloped countries is augmenting the global HPV therapeutics market. “The severe side effects associated with HPV vaccines have prompted several governments and organizations across the globe to ban their use,” says a TMR analyst. Thus, the vaccine market has been witnessing a steep fall since 2010, which in turn, is likely to augur well for the growth of the HPV therapeutics market.
The increasing global demand for low-cost generic versions of CMV therapeutics is leading to the expansion of customer base and higher market penetration, especially in low- and middle-income countries. This is working in favor of the overall CMV therapeutics market. Moreover, the high seropositivity, coupled with the increasing pool of immunocompromised patients, is providing a significant push to the market.
Advent of Highly Active Antiretroviral Therapy (HAART) to Dent Demand for CMV Therapeutics
In recent times, minimally invasive surgeries are gaining popularity due to their fewer side effects and cost-effectiveness. This, in turn, is limiting the widespread adoption of HPV therapeutics. Despite increasing awareness programs being organized across the globe, these programs are unable to penetrate the economies that report declining diagnostic rates. Hence, the decreasing diagnosis rates reduce the therapeutics intervention opportunities, which ultimately negatively influences the HPV therapeutics market.
With the introduction of highly active antiretroviral therapy (HAART), the HIV mortality rate has declined dramatically. With manageable CD4 counts, the prevalence of CMV infections in HIV patients also decreased considerably. As a result, the dependence on CMV therapeutics is likely to reduce significantly.
The information presented in this review is based on a Transparency Market Research report, titled,“Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast, 2014–2020.”
The global HPV and CMV therapeutics market is segmented as follows:
HPV Therapeutics Market, by Drug Class
- Keratolytic Agents
- Anti-neoplastic Agents
HPV Therapeutics Market, by Applications
- Genital Warts
- Genital Cancer
- Epidermodysplasia Verruciformis
- Oral Papillomas
- Others (Oropharyngeal cancer, laryngeal papillomatosis and others)
CMV Therapeutics Market, by Drug Type
CMV Therapeutics Market, by Applications
- CMV Retinitis
- Gastrointestinal ulcers
- Others (Mouth ulcers, pharyngitis)
Global HPV and CMV Therapeutics Market, by Geography
- North America
- Asia Pacific
- South America
- Rest of the World
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453